Gsk (GSK) Interest & Investment Income (2009 - 2026)

On a TTM basis, Gsk's Interest & Investment Income came in at $371.24 million as of Sep 30, 2026, up 73.9% year-over-year; for the year ended Dec 31, 2025, it was $222.83 million, up 42.9% from the prior year.

• Annual Interest & Investment Income has increased for four straight years, with a five-year compound annual growth rate of 32.8% (years ended Dec 2020 to Dec 2025).
• Across earlier years, Interest & Investment Income came in at $155.95 million in the year ended Dec 31, 2024 (+9.0%), $143.04 million in the year ended Dec 31, 2023 (+52.1%), $94.06 million in the year ended Dec 31, 2022 (+388.3%) and $19.26 million in the year ended Dec 31, 2021 (-64.3%).
• Quarterly Interest & Investment Income has ranged from $1.35 million in the quarter ended Dec 31, 2021 to $224.8 million in the quarter ended Dec 31, 2025 over the past five years.
• On a year-over-year basis, Interest & Investment Income rose in six of the last eight quarters, with growth averaging 72.5%.
• Peak year-over-year performance for Interest & Investment Income in the last five years was growth of 415.1% in the quarter ended Dec 31, 2025, against a decline of 79.6% in the quarter ended Dec 31, 2021 at the low end.
• Per Business Quant, the preceding three quarters came in at $77.82 million (quarter ended Jun 30, 2026), $29.66 million (quarter ended Mar 31, 2026) and $224.8 million (quarter ended Dec 31, 2025).